A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome

Chest

Volumn 153, Issue 4, 2018, Pages 805-815

  Lee, Chien Chang ^a   Lee, Meng tse Gabriel ^a   Hsu, Tzu Chun ^a   Porta, Lorenzo ^b   Chang, Shy Shin ^c   Yo, Chia Hung ^d   Tsai, Kuang Chau ^d   Lee, Matthew ^e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF MILAN   (Italy)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e Medical Wisdom Consultants   (United States)

Author keywords

atorvastatin; rosuvastatin; sepsis; simvastatin; statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROSUVASTATIN; SIMVASTATIN; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT;

AGED; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; MULTICENTER STUDY; RESPIRATORY FAILURE; TAIWAN; TREATMENT OUTCOME;

AGED; ANTI-INFECTIVE AGENTS; ATORVASTATIN; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; RESPIRATORY INSUFFICIENCY; ROSUVASTATIN CALCIUM; SEPSIS; SIMVASTATIN; TAIWAN; TREATMENT OUTCOME;

EID: 85044128957     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.09.024     Document Type: Article

References (43)

1. Rhodes, A., Evans, L.E., Alhazzani, W., et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:3 (2017), 304–377.
2. Rhodes, A., Evans, L.E., Alhazzani, W., et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45:3 (2017), 486–552.
3. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M.R., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:7 (2001), 1303–1310.
4. Fleischmann, C., Scherag, A., Adhikari, N.K., et al., International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations. Am J Respir Crit Care Med 193:3 (2016), 259–272.
5. Gao, F., Linhartova, L., Johnston, A.M., Thickett, D.R., Statins and sepsis. Br J Anaesth 100:3 (2008), 288–298.
6. Crisby, M., Modulation of the inflammatory process by statins. Timely Top Med Cardiovasc Dis, 9, 2005, E3.
7. Crisby, M., Modulation of the inflammatory process by statins. Drugs Today (Barc) 39:2 (2003), 137–143.
8. Hackam, D.G., Mamdani, M., Li, P., Redelmeier, D.A., Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367:9508 (2006), 413–418.
9. Al Harbi, S.A., Tamim, H.M., Arabi, Y.M., Association between statin therapy and outcomes in critically ill patients: a nested cohort study. BMC Clin Pharmacol, 11, 2011, 12.
10. Wan, Y.D., Sun, T.W., Kan, Q.C., Guan, F.X., Zhang, S.G., Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies. Crit Care, 18(2), 2014, R71.
11. Mansur, A., Steinau, M., Popov, A.F., Ghadimi, M., Beissbarth, T., Bauer, M., Hinz, J., Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study. BMC Med, 13, 2015, 128.
12. Brookhart, M.A., Patrick, A.R., Dormuth, C., et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166:3 (2007), 348–354.
13. Dinglas, V.D., Hopkins, R.O., Wozniak, A.W., et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax 71:5 (2016), 401–410.
14. Deshpande, A., Pasupuleti, V., Rothberg, M.B., Statin therapy and mortality from sepsis: a meta-analysis of randomized trials. Am J Med 128:4 (2015), 410–417.e411.
15. McAuley, D.F., Laffey, J.G., O'Kane, C.M., et al. HARP-2 Investigators, Irish Critical Care Trials Group. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371:18 (2014), 1695–1703.
16. Heart, T.N., Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med, 370(23), 2014, 2191.
17. Hennessy, E., Adams, C., Reen, F.J., O'Gara, F., Is there potential for repurposing statins as novel antimicrobials?. Antimicrob Agents Chemother 60:9 (2016), 5111–5121.
18. Ting, M., Whitaker, E.J., Albandar, J.M., Systematic review of the in vitro effects of statins on oral and perioral microorganisms. Eur J Oral Sci 124:1 (2016), 4–10.
19. Jerwood, S., Cohen, J., Unexpected antimicrobial effect of statins. J Antimicrob Chemother 61:2 (2008), 362–364.
20. Shepherd, J., Hunninghake, D.B., Barter, P., McKenney, J.M., Hutchinson, H.G., Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 91:5A (2003), 11C–17C.
21. Kamat, S.A., Gandhi, S.K., Davidson, M., Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin 23:5 (2007), 1121–1130.
22. Masadeh, M., Mhaidat, N., Alzoubi, K., Al-Azzam, S., Alnasser, Z., Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob, 11, 2012, 13.
23. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper presented at: Twenty-Sixth Annual SAS Users Group International Conference; April 22-25, 2001, Long Beach, CA.
24. Rassen, J.A., Glynn, R.J., Rothman, K.J., Setoguchi, S., Schneeweiss, S., Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf 21:7 (2012), 697–709.
25. Rassen, J.A., Shelat, A.A., Franklin, J.M., Glynn, R.J., Solomon, D.H., Schneeweiss, S., Matching by propensity score in cohort studies with three treatment groups. Epidemiology 24:3 (2013), 401–409.
26. Ou, S.-Y., Chu, H., Chao, P.-W., Effect of the use of low and high potency statins and sepsis outcomes. Intensive Care Med 40:10 (2014), 1509–1517.
27. Wilhelms, S.B., Huss, F.R., Granath, G., Sjöberg, F., Assessment of incidence of severe sepsis in Sweden using different ways of abstracting International Classification of Diseases codes: difficulties with methods and interpretation of results. Crit Care Med 38:6 (2010), 1442–1449.
28. Gaieski, D.F., Edwards, J.M., Kallan, M.J., Carr, B.G., Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41:5 (2013), 1167–1174.
29. Serody, J.S., Berrey, M.M., Albritton, K., et al. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant 26:5 (2000), 533–538.
30. Glerant, J.C., Hellmuth, D., Schmit, J.L., Ducroix, J.P., Jounieaux, V., Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission. Respir Med 93:3 (1999), 208–212.
31. Iwashyna, T.J., Angus, D.C., Declining case fatality rates for severe sepsis: Good data bring good news with ambiguous implications. JAMA 311:13 (2014), 1295–1297.
32. Merx, M.W., Liehn, E.A., Janssens, U., et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:21 (2004), 2560–2565.
33. Zhang, S., Luo, L., Wang, Y., et al. Simvastatin protects against T cell immune dysfunction in abdominal sepsis. Shock 38:5 (2012), 524–531.
34. Zhang, S., Rahman, M., Zhang, S., Qi, Z., Thorlacius, H., Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. J Leukoc Biol 89:5 (2011), 735–742.
35. Wang, C.C., Yang, P.W., Yang, S.F., Hsieh, K.P., Tseng, S.P., Lin, Y.C., Topical simvastatin promotes healing of Staphylococcus aureus-contaminated cutaneous wounds. Int Wound J 13:6 (2016), 1150–1157.
36. Graziano, T.S., Cuzzullin, M.C., Franco, G.C., et al. Statins and antimicrobial effects: simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS One, 10(5), 2015, e0128098.
37. Thangamani, S., Mohammad, H., Abushahba, M.F.N., et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci Rep, 5, 2015, 16407.
38. Emani, S., Gunjiganur, G.V., Mehta, D.S., Determination of the antibacterial activity of simvastatin against periodontal pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: an in vitro study. Contemp Clin Dent 5:3 (2014), 377–382.
39. Welsh, A.M., Kruger, P., Faoagali, J., Antimicrobial action of atorvastatin and rosuvastatin. Pathology 41:7 (2009), 689–691.
40. Haeri, M.R., White, K., Qharebeglou, M., Ansar, M.M., Cholesterol suppresses antimicrobial effect of statins. Iran J Basic Med Sci 18:12 (2015), 1253–1256.
41. Schachter, M., Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:1 (2005), 117–125.
42. Plenge, J.K., Hernandez, T.L., Weil, K.M., et al. Simvastatin lowers C-reactive protein within 14 days an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:12 (2002), 1447–1452.
43. Chen, W.T., Krishnan, G.M., Sood, N., Kluger, J., Coleman, C.I., Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg 140:2 (2010), 364–372.